Compare Ascendis Pharma A/S (ASND) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs General Motors Company — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while General Motors Company trades at $77.77 (market cap $70.19B). The key difference: General Motors Company is far larger — about 4× Ascendis Pharma A/S's market cap, and General Motors Company pays a 0.92% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GM | |
|---|---|---|
Market Cap | $17.74B | $70.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $86.38 |
52-Week Low | $163.32 | $48.89 |
Enterprise Value | $18.11B | $173.53B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
General Motors (GM) trades at $77.85, up 1.57% with a bearish technical signal despite three consecutive quarterly earnings beats. The company maintains strong cash flow generation ($26.9B operating cash flow in 2025) and trades at discounted valuations (P/S 0.4, P/B 1.12). Recent news highlights GM's strategic pivot into energy and battery technology partnerships as automotive sales face industry headwinds.
GM presents a value opportunity with analyst consensus price target of $100.27 (29% upside) but faces execution risks in EV transition and margin pressure. The stock's outlook depends on Q2 earnings delivering clean cash flow and sustained margin improvement amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
